Glick, MatthewBaxter, ChaseLopez, DavidMufti, KashifSawada, StephenLahm, Tim2022-01-102022-01-102020-10Glick, M., Baxter, C., Lopez, D., Mufti, K., Sawada, S., & Lahm, T. (2020). Releasing the brakes: A case report of pulmonary arterial hypertension induced by immune checkpoint inhibitor therapy. Pulmonary Circulation, 10(4), 1–4. https://doi.org/10.1177/20458940209609672045-8940, 2045-8940https://hdl.handle.net/1805/27337Immune checkpoint inhibitors successfully treat various malignancies by inducing an immune response to tumor cells. However, their use has been associated with a variety of autoimmune disorders, such as diabetes, hepatitis, and pneumonitis. Pulmonary arterial hypertension due to checkpoint inhibitor use has not yet been described. We present a novel case of pulmonary arterial hypertension associated with systemic lupus erythematosus and Sjogren’s syndrome overlap that was induced by therapy with the checkpoint inhibitor durvalumab.en-USAttribution-NonCommercial 4.0 Internationalautoimmune diseasedurvalumabimmunotherapyprogrammed death-ligand 1 inhibitorright heart failureArticle